🇺🇸 FDA
Pipeline program

Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo

ALXN1210-DGF-321

Phase 3 small_molecule active

Quick answer

Ultomiris 1,100 mg/11 mL concentrate for solution for infusion, Anti C5 Complement mAb Placebo for Delayed Graft Function after Kidney Transplantation is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
Delayed Graft Function after Kidney Transplantation
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials